MRC.WA
Mercator Medical S.A. [MRC.WA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
MRC.WA Stock Summary
Top 10 Correlated ETFs
MRC.WA
Top 10 Correlated Stocks
MRC.WA
In the News
MRC.WA Financial details
Company Rating
Neutral
Market Cap
379.32M
Income
-234.42M
Revenue
469.82M
Book val./share
94.38
Cash/share
37.31
Dividend
2.5
Dividend %
5.33%
Employees
888
Optionable
No
Shortable
Yes
Earnings
29 May 2024
P/E
-1.91
Forward P/E
-
PEG
0.12
P/S
0.98
P/B
0.5
P/C
1.14
P/FCF
-16.29
Quick Ratio
4.43
Current Ratio
7.46
Debt / Equity
0.01
LT Debt / Equity
0.01
-
-
EPS (TTM)
-24.02
EPS next Y
-
EPS next Q
-
EPS this Y
-144.24%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
5.23%
Revenue Q/Q
-2.82%
EPS Q/Q
-301%
-
-
-
-
SMA20
-4.55%
SMA50
-6.67%
SMA100
2.44%
Inst Own
-
Inst Trans
-
ROA
-23%
ROE
-25%
ROC
-0.09%
Gross Margin
13%
Oper. Margin
-18%
Profit Margin
-50%
Payout
-10%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
38.82-51.9
52W High
-16.76%
52W Low
+11.71%
RSI
42
Rel Volume
0.32
Avg Volume
5.79K
Volume
1.86K
Perf Week
-3.85%
Perf Month
-5.25%
Perf Quarter
2.54%
Perf Half Y
2.24%
-
-
-
-
Beta
2.717
-
-
Volatility
0.46%, 1.07%
Prev Close
0.83%
Price
42.45
Change
2.41%
MRC.WA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 39.7 | 51.03 | 174.83 | 170.66 | 55.53 | |
| Net income per share | 0.71 | -0.19 | 88.66 | 44.15 | -19.53 | |
| Operating cash flow per share | -0.78 | 3.64 | 67.91 | 49.69 | 4.18 | |
| Free cash flow per share | -4.84 | 2.17 | 66.43 | 32.23 | -7.05 | |
| Cash per share | 1.53 | 1.4 | 52.15 | 52.89 | 43.17 | |
| Book value per share | 12.5 | 12.57 | 99.13 | 113.01 | 103.24 | |
| Tangible book value per share | 12.29 | 12.34 | 99.06 | 112.19 | 100.75 | |
| Share holders equity per share | 12.5 | 12.57 | 99.13 | 113.01 | 103.24 | |
| Interest debt per share | 14.77 | 14.72 | 0.78 | 0.49 | 0.38 | |
| Market cap | 114.36M | 105.36M | 4.43B | 981.82M | 482.17M | |
| Enterprise value | 249.4M | 238.85M | 4.03B | 647.04M | 262.22M | |
| P/E ratio | 15.31 | -51.88 | 4.76 | 2.2 | -2.53 | |
| Price to sales ratio | 0.27 | 0.19 | 2.41 | 0.57 | 0.89 | |
| POCF ratio | -13.92 | 2.73 | 6.21 | 1.95 | 11.82 | |
| PFCF ratio | -2.23 | 4.59 | 6.35 | 3.01 | -7 | |
| P/B Ratio | 0.86 | 0.79 | 4.26 | 0.86 | 0.48 | |
| PTB ratio | 0.86 | 0.79 | 4.26 | 0.86 | 0.48 | |
| EV to sales | 0.59 | 0.44 | 2.2 | 0.37 | 0.48 | |
| Enterprise value over EBITDA | 9.17 | 8.66 | 3.78 | 1.17 | -5.43 | |
| EV to operating cash flow | -30.36 | 6.2 | 5.66 | 1.29 | 6.43 | |
| EV to free cash flow | -4.86 | 10.4 | 5.78 | 1.98 | -3.81 | |
| Earnings yield | 0.07 | -0.02 | 0.21 | 0.46 | -0.4 | |
| Free cash flow yield | -0.45 | 0.22 | 0.16 | 0.33 | -0.14 | |
| Debt to equity | 1.14 | 1.11 | 0 | 0 | 0 | |
| Debt to assets | 0.4 | 0.38 | 0 | 0 | 0 | |
| Net debt to EBITDA | 4.97 | 4.84 | -0.37 | -0.61 | 4.56 | |
| Current ratio | 1.19 | 1.25 | 4.57 | 6.87 | 11.63 | |
| Interest coverage | 3.16 | 1.34 | 265.02 | 3.89K | -221.76 | |
| Income quality | -1.17 | -18.97 | 0.76 | 1.13 | -0.21 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0.01 | 0 | 0 | |
| Sales general and administrative to revenue | 0.05 | 0.05 | 0.02 | 0.04 | 0.11 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.01 | 0.01 | 0 | 0.01 | 0.02 | |
| Capex to operating cash flow | 5.24 | -0.4 | -0.02 | -0.35 | -2.69 | |
| Capex to revenue | -0.1 | -0.03 | -0.01 | -0.1 | -0.2 | |
| Capex to depreciation | -3.04 | -0.89 | -0.84 | -9.16 | -4.27 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | -0.01 | |
| Graham number | 14.08 | 7.37 | 444.68 | 335.05 | 212.98 | |
| ROIC | 0.05 | -0.04 | 0.9 | 0.37 | -0.07 | |
| Return on tangible assets | 0.02 | -0.01 | 0.72 | 0.35 | -0.18 | |
| Graham Net | -11.81 | -12.06 | 46.88 | 59.34 | 51.25 | |
| Working capital | 31.12M | 38.41M | 855.63M | 781.12M | 637.6M | |
| Tangible asset value | 130.17M | 130.69M | 1.04B | 1.14B | 984.42M | |
| Net current asset value | -56.31M | -61.19M | 849.35M | 770.86M | 623.71M | |
| Invested capital | 1.14 | 1.11 | 0 | 0 | 0 | |
| Average receivables | 63.71M | 82.96M | 101.59M | 120.51M | 97.26M | |
| Average payables | 74.61M | 85.43M | 94.81M | 78.85M | 46.45M | |
| Average inventory | 85.59M | 93.32M | 148.21M | 218.7M | 215.53M | |
| Days sales outstanding | 68.72 | 58.61 | 23.17 | 26.33 | 47.04 | |
| Days payables outstanding | 92.53 | 75.99 | 56.98 | 19.98 | 28.75 | |
| Days of inventory on hand | 109.94 | 76.32 | 117.27 | 80.58 | 161.25 | |
| Receivables turnover | 5.31 | 6.23 | 15.76 | 13.86 | 7.76 | |
| Payables turnover | 3.94 | 4.8 | 6.41 | 18.27 | 12.69 | |
| Inventory turnover | 3.32 | 4.78 | 3.11 | 4.53 | 2.26 | |
| ROE | 0.06 | -0.02 | 0.89 | 0.39 | -0.19 | |
| Capex per share | -4.07 | -1.47 | -1.48 | -17.46 | -11.22 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 14.22 | 12.03 | 11.62 | 12.72 | 12.36 | |
| Net income per share | 1.98 | -21.16 | -1.85 | 1 | -2.01 | |
| Operating cash flow per share | 0.78 | 2.76 | -0.69 | 1.94 | -0.71 | |
| Free cash flow per share | -1.88 | -0.55 | -2.31 | 0.96 | -0.99 | |
| Cash per share | 45.67 | 43.17 | 40.37 | 43.06 | 37.31 | |
| Book value per share | 122.84 | 103.24 | 99.98 | 93.13 | 94.38 | |
| Tangible book value per share | 121.2 | 100.75 | 97.29 | 90.04 | 90.97 | |
| Share holders equity per share | 122.84 | 103.24 | 99.98 | 93.13 | 94.38 | |
| Interest debt per share | 0.45 | 0.35 | 0.59 | 0.6 | 0.58 | |
| Market cap | 473.28M | 482.17M | 433.49M | 415.39M | 398.4M | |
| Enterprise value | 221.35M | 262.22M | 257.59M | 174.33M | 237.61M | |
| P/E ratio | 6.11 | -0.58 | -6.03 | 10.85 | -5.18 | |
| Price to sales ratio | 3.41 | 4.1 | 3.84 | 3.42 | 3.37 | |
| POCF ratio | 62 | 17.85 | -64.34 | 22.37 | -59.06 | |
| PFCF ratio | -25.83 | -89.16 | -19.31 | 45.13 | -42.02 | |
| P/B Ratio | 0.39 | 0.48 | 0.45 | 0.47 | 0.44 | |
| PTB ratio | 0.39 | 0.48 | 0.45 | 0.47 | 0.44 | |
| EV to sales | 1.59 | 2.23 | 2.28 | 1.44 | 2.01 | |
| Enterprise value over EBITDA | 8.25 | -3.91 | -49.89 | 17.06 | -10.36 | |
| EV to operating cash flow | 29 | 9.71 | -38.23 | 9.39 | -35.22 | |
| EV to free cash flow | -12.08 | -48.49 | -11.48 | 18.94 | -25.06 | |
| Earnings yield | 0.04 | -0.43 | -0.04 | 0.02 | -0.05 | |
| Free cash flow yield | -0.04 | -0.01 | -0.05 | 0.02 | -0.02 | |
| Debt to equity | 0 | 0 | 0.01 | 0.01 | 0.01 | |
| Debt to assets | 0 | 0 | 0.01 | 0.01 | 0.01 | |
| Net debt to EBITDA | -9.39 | 3.28 | 34.07 | -23.59 | 7.01 | |
| Current ratio | 13.48 | 11.63 | 14.79 | 7.15 | 7.46 | |
| Interest coverage | 262.74 | -1.32K | -1.47K | -298.9 | -63.49 | |
| Income quality | 0.42 | -0.13 | 0.37 | 2.18 | 0.57 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0.06 | |
| Payout ratio | 0 | 0 | 0 | 0 | -1.24 | |
| Sales general and administrative to revenue | 0.12 | 0.16 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | |
| Capex to operating cash flow | -3.4 | -1.2 | 2.33 | -0.5 | 0.41 | |
| Capex to revenue | -0.19 | -0.28 | -0.14 | -0.08 | -0.02 | |
| Capex to depreciation | -3.79 | -4.38 | -2.1 | -2.85 | -2.04 | |
| Stock based compensation to revenue | 0 | -0.04 | 0 | 0 | 0 | |
| Graham number | 74.02 | 221.73 | 64.53 | 45.82 | 65.4 | |
| ROIC | 0.01 | -0.03 | -0.02 | -0.01 | -0.01 | |
| Return on tangible assets | 0.02 | -0.2 | -0.02 | 0.01 | -0.02 | |
| Graham Net | 56.13 | 51.25 | 48.46 | 44.12 | 41.25 | |
| Working capital | 721.26M | 637.6M | 600.08M | 536.86M | 519.84M | |
| Tangible asset value | 1.18B | 984.42M | 944.32M | 859.79M | 868.71M | |
| Net current asset value | 709.65M | 623.71M | 577.31M | 507.99M | 494.94M | |
| Invested capital | 0 | 0 | 0.01 | 0.01 | 0.01 | |
| Average receivables | 77.5M | 74.46M | 79.11M | 88.47M | 91.68M | |
| Average payables | 38.05M | 32.5M | 31.1M | 34.07M | 50.56M | |
| Average inventory | 241.7M | 212.65M | 178.86M | 138.42M | 131.8M | |
| Days sales outstanding | 51.18 | 53.55 | 70.47 | 65.68 | 72.19 | |
| Days payables outstanding | 22.31 | 31.96 | 27.01 | 31.82 | 52.65 | |
| Days of inventory on hand | 171.52 | 179.23 | 160.52 | 91.37 | 127.47 | |
| Receivables turnover | 1.76 | 1.68 | 1.28 | 1.37 | 1.25 | |
| Payables turnover | 4.03 | 2.82 | 3.33 | 2.83 | 1.71 | |
| Inventory turnover | 0.52 | 0.5 | 0.56 | 0.98 | 0.71 | |
| ROE | 0.02 | -0.2 | -0.02 | 0.01 | -0.02 | |
| Capex per share | -2.66 | -3.32 | -1.62 | -0.98 | -0.29 |
MRC.WA Frequently Asked Questions
What is Mercator Medical S.A. stock symbol ?
Mercator Medical S.A. is a PL stock and trading under the symbol MRC.WA
What is Mercator Medical S.A. stock quote today ?
Mercator Medical S.A. stock price is $42.45 today.
Is Mercator Medical S.A. stock public?
Yes, Mercator Medical S.A. is a publicly traded company.
Company Profile
- Volume Average 5.79K
- Market Capitalization 379.32M
- Employee 888
- CEO Dr. Wieslaw Zyznowski Ph.D.
- Headquarters Kraków,PL
- IPO Date 2014-01-17
-
Website
https://mercatormedical.eu 
Mercator Medical S.A., together with its subsidiaries, manufactures and distributes disposable medical gloves, dressings, and non-woven fabric products in Europe and internationally. The company offers surgical and protective, sterile examination and protective, and household gloves; glove brackets; and single-use clothing, including caps, masks, gowns, shoe covers, surgical shirts, sleeve protectors, and patient's shirts. It also provides surgical drape sheets; sterile drapes with non-adhesive opening; surgical sets; and accessories, such as apparatus covers, limb protectors, table covers, camera covers, adhesive pockets for surgical instruments, and self-adhesive nonwoven tapes. The company markets its products under the nitrylex, opero, MERCATOR, Ansell, dermagel, santex, comfort, vinylex, iNtouch, ambulance, and ideal brands. It serves beauty; hotels, restaurants, catering, and private cleaning; agri-food; automotive; home and garden; education; and retail industries, as well as medical customers comprising healthcare units, industrial plants, retail chains, and pharmaceutical wholesalers. The company was founded in 1989 and is headquartered in Kraków, Poland. Mercator Medical S.A. operates as a subsidiary of Anabaza RAIF V.C.I.C. Ltd.
